Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 72.00M | 1.21B | 1.68B | -11.91B | 1.76B |
| Total Depreciation and Amortization | 1.85B | 2.63B | 2.62B | 2.47B | 2.45B |
| Total Amortization of Deferred Charges | -- | -- | -28.00M | 28.00M | -- |
| Total Other Non-Cash Items | 1.24B | 41.00M | 421.00M | 12.05B | -814.00M |
| Change in Net Operating Assets | 1.28B | 1.71B | -2.37B | 198.00M | 855.00M |
| Cash from Operations | 4.44B | 5.59B | 2.33B | 2.83B | 4.25B |
| Capital Expenditure | -378.00M | -324.00M | -262.00M | -284.00M | -330.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -47.00M | -348.00M | -1.37B | -20.05B | -581.00M |
| Divestitures | 333.00M | 255.00M | 270.00M | 241.00M | 241.00M |
| Other Investing Activities | -104.00M | 198.00M | 46.00M | 478.00M | -676.00M |
| Cash from Investing | -196.00M | -219.00M | -1.32B | -19.62B | -1.35B |
| Total Debt Issued | -405.00M | 95.00M | 326.00M | 15.95B | 4.22B |
| Total Debt Repaid | 0.00 | -2.75B | -3.13B | -- | -2.12B |
| Issuance of Common Stock | -- | -- | -- | -- | 25.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.22B | -1.22B | -1.22B | -1.21B | -1.16B |
| Other Financing Activities | -19.00M | 16.00M | -6.00M | -97.00M | -- |
| Cash from Financing | -1.64B | -3.85B | -4.02B | 14.64B | 967.00M |
| Foreign Exchange rate Adjustments | -147.00M | 77.00M | -22.00M | -45.00M | 78.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.45B | 1.60B | -3.04B | -2.19B | 3.95B |
